Immunogenicity 421
Sample ID
None
Response
Negative
Tumor Type
Melanoma
Gene Symbol
NLRC4
Transcript ID
None
HLA INFO
A*24:02
TCR INFO
No TCR info found!
Full length protein sequence (788 aa)
MNFIK
1
DNSRA
6
LIQRM
11
GMTVI
16
KQITD
21
DLFVW
26
NVLNR
31
EEVNI
36
ICCEK
41
VEQDA
46
ARGII
51
HMILK
56
KGSES
61
CNLFL
66
KSLKE
71
WNYPL
76
FQDLN
81
GQSLF
86
HQTSE
91
GDLDD
96
LAQDL
101
KDLYH
106
TPSFL
111
NFYPL
116
GEDID
121
IIFNL
126
KSTFT
131
EPVLW
136
RKDQH
141
HHRVE
146
QLTLN
151
GLLQA
156
LQSPC
161
IIEGE
166
SGKGK
171
STLLQ
176
RIAML
181
WGSGK
186
CKALT
191
KFKFV
196
FFLRL
201
SRAQG
206
GLFET
211
LCDQL
216
LDIPG
221
TIRKQ
226
TFMAM
231
LLKLR
236
QRVLF
241
LLDGY
246
NEFKP
251
QNCPE
256
IEALI
261
KENHR
266
FKNMV
271
IVTTT
276
TECLR
281
HIRQF
286
GALTA
291
EVGDM
296
TEDSA
301
QALIR
306
EVLIK
311
ELAEG
316
LLLQI
321
QKSRC
326
LRNLM
331
KTPLF
336
VVITC
341
AIQMG
346
ESEFH
351
SHTQT
356
TLFHT
361
FYDLL
366
IQKNK
371
HKHKG
376
VAASD
381
FIRSL
386
DHCGD
391
LALEG
396
VFSHK
401
FDFEL
406
QDVSS
411
VNEDV
416
LLTTG
421
LLCKY
426
TAQRF
431
KPKYK
436
FFHKS
441
FQEYT
446
AGRRL
451
SSLLT
456
SHEPE
461
EVTKG
466
NGYLQ
471
KMVSI
476
SDITS
481
TYSSL
486
LRYTC
491
GSSVE
496
ATRAV
501
MKHLA
506
AVYQH
511
GCLLG
516
LSIAK
521
RPLWR
526
QESLQ
531
SVKNT
536
TEQEI
541
LKAIN
546
INSFV
551
ECGIH
556
LYQES
561
TSKSA
566
LSQEF
571
EAFFQ
576
GKSLY
581
INSGN
586
IPDYL
591
FDFFE
596
HLPNC
601
ASALD
606
FIKLD
611
FYGGA
616
MASWE
621
KAAED
626
TGGIH
631
MEEAP
636
ETYIP
641
SRAVS
646
LFFNW
651
KQEFR
656
TLEVT
661
LRDFS
666
KLNKQ
671
DIRYL
676
GKIFS
681
SATSL
686
RLQIK
691
RCAGV
696
AGSLS
701
LVLST
706
CKNIY
711
SLMVE
716
ASPLT
721
IEDER
726
HITSV
731
TNLKT
736
LSIHD
741
LQNQR
746
LPGGL
751
TDSLG
756
NLKNL
761
TKLIM
766
DNIKM
771
NEEDA
776
IKLDN
781
SSL
786
Mutation Information
DNA mutation:
None
Peptide Range:
360 ~ 381
Mut AA position:
368 (9 in Wild Type peptide)
Alignment
Wild Type:
"----TTLFHTFYDL--------
||||||||.|
Mutant:
SHTQTTLFHTFYELLIQKNKHK"
Nature, 2017
An immunogenic personal neoantigen vaccine for patients with melanomaGene Name (from Reference) NLRC4
Checkpoint
Blockade
None
ACT
None
Vaccination
None
Curative
Effect
None
minimal_peptide
None
Antigen
Type
peptide
T-cell
Source
PBMCs
APC
Type
autologous APCs
Assay
IFNg ELISPOT assay